NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR FROM AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL.
BURNING ROCK BIOTECH LIMITED – Admission to trading on the London Stock Exchange
November 1, 2022
Neither this announcement, nor anything contained therein, nor anything in the prospectus (“Prospectus”) referred to herein shall form the basis of, or be relied upon in connection with, any offer or undertaking in any jurisdiction her. Investors may not subscribe for or purchase the securities referred to in this announcement except solely on the basis of the information in the prospectus, including the risk factors set forth therein, published in connection with the acceptance (“Admission”) of the Company’s American Depositary Shares (“ADS”). on the standard listing segment of the FCA Official List and to trading on the main market of the London Stock Exchange plc (“LSE”) by direct listing (“Direct Listing”). A copy of the prospectus dated October 27, 2022 is available for inspection on the Company’s website at http://ir.brbiotech.com/.
LONDON, Nov. 01, 2022 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR , the “Company” or “Burning Rock”) announces that its announcements on October 27, 2022 have been published today. admitted to the standard listing segment of the FCA Official List and to trading on the LSE Main Market under the symbol “BNR”.
Burning Rock’s ADSs will continue to be listed and traded on the Nasdaq Global Market, and these ADSs will be fully exchangeable with ADSs listed on the LSE. Custodial and depository connections have been established between Euroclear, Clearstream and DTC to facilitate intermarket transfers of ADSs in connection with secondary market trading.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR ), whose mission is to protect life through science, focuses on the application of next-generation sequencing (NGS) technology in precision oncology. Its business includes i) testing NGS-based therapy selection for late-stage cancer patients and ii) early cancer detection that has moved beyond R&D from proof-of-concept to clinical validation.
For more information about Burning Rock, visit: www.brbiotech.com.
Important legal information
The information in this announcement is for background purposes only and is not purported to be complete or complete, nor does this announcement constitute or form part of any invitation or inducement to engage in investment activity. No person may rely on the information in this publication or its accuracy, fairness or completeness for any purpose. The content of this post should not be construed as legal, financial or tax advice.
This publication is not for publication, publication or distribution, directly or indirectly, in or to Australia, Canada, South Africa or Japan or any other jurisdiction where or to any person for whom doing so would constitute a violation of any applicable law or regulation.
These materials do not constitute or form part of any offer or solicitation to sell or issue or any solicitation of any offer to buy or subscribe for any ADSs or any other securities, nor (or any part thereof) or the facts of its distribution , form the basis of or be relied upon in connection with any contract.
This announcement may include forward-looking statements that are based on current expectations and predictions about future events. These statements may include, without limitation, any statements that are preceded by words that follow or include words such as “goal,” “believe,” “expect,” “aim,” “intend,” “may,” ” I guess”, “I estimate”. “, “plan”, “project”, “will”, “may have”, “probably”, “should”, “would”, “could” and all other words and expressions of a similar or negative meaning. These forward-looking statements are subject to risks, uncertainties and assumptions about Burning Rock and its affiliates. Given these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur. Past performance cannot be relied upon as a guide to future performance and should not be taken as a representation that trends or activities underlying past performance will continue in the future. No representation or guarantee is or will be given that any forward-looking statement will be realized. Forward-looking statements in this announcement speak only as of the date of this announcement.
Burning Rock expressly disclaims any obligation or commitment to update, review or revise any forward-looking statements contained in this announcement and disclaims any obligation to update its view of any risks or uncertainties described herein or to make public the results of any any future revisions. -fictitious statements in this publication, whether as a result of new information, future developments or otherwise, unless required by law.
The information in this post is subject to change. Persons viewing this publication must ensure that they fully understand and accept the risks set forth in the prospectus.
Unless otherwise stated, market, industry and competitive data are estimates (and therefore approximate) and should be treated with caution. Such information has not been audited or independently verified, nor has the Group identified the underlying economic assumptions on which it is based. Some of the information in this release, including financial, statistical and operational information, is rounded. Due to rounding, the data totals presented in this publication may differ slightly from the actual arithmetic totals of these data.
For the avoidance of doubt, the content of the Company’s website is not incorporated by reference into, and does not form part of, this announcement.